Skip to main content
. 2021 Apr 28;12:2461. doi: 10.1038/s41467-021-22941-3

Fig. 7. The CRL inhibitor pevonedistat/MLN4924 stabilizes ETV5 and improves diet-induced or leptin deficiency-induced obesity/diabetes.

Fig. 7

a, e Levels of ETV5 in HFD-fed mice (a) or ob/ob mice (e), with/without MLN4924 treatment. b Body weight of 8-week-old WT mice fed HFD or NCD for the indicated time period, with/without MLN4924 treatment (15 mg/kg, twice weekly for the first 6 weeks; n = 5, ***p < 0.001, calculated by two-way repeated measures ANOVA testing treatment × time effect). Data are presented as mean ± SEM. c, d Feeding and fasting insulin (c) and glucose (d) levels in HFD or NCD mice with/without MLN4924 treatment (n = 5). Data are presented as mean ± SEM. P values were calculated by two-tailed Student’s t test. f Body weight of ob/ob mice with/without MLN4924 treatment (15 mg/kg, twice weekly; n = 5, ***p < 0.001, calculated by two-way repeated measures ANOVA testing treatment × time effect). Data are presented as mean ± SEM. g, h Feeding and fasting glucose (g) and insulin (h) levels in ob/ob mice with/without MLN4924 treatment (n = 5). Data are presented as mean ± SEM. P values were calculated by two-tailed Student’s t test.